Refocus On China: Ark Bio Evolves As It Plans Shanghai Listing
Eyes R&D In Less Crowded Sectors
Shanghai-based Ark Biosciences has expanded its pipeline from the RSV-targeting drug ziresovir, licensed from Roche, to pediatric and fibrosis treatments, where there are largely untapped opportunities in China. In a strategy shift, the company is betting on the domestic market instead of going global.
